Monday Dec 23, 2024
Monday Dec 23, 2024

BioMarin’s gene therapy

$2.9 million gene therapy for severe hemophilia

Jul 1, 2023
U.S. officials on Thursday approved drugmaker BioMarin’s gene therapy for the most common form of hemophilia.
Nepal's First Online News Portal
Published by Nepalnews Pvt Ltd
Editor: Raju Silwal
Information Department Registration No. 1505 / 076-77

Contact

Kathmandu, Nepal,


Newsroom
##

E-mail
nepalnewseditor@gmail.com

Terms of Use Disclaimer
© NepalNews. 2021 All rights reserved. | Nepal's First News Portal